MedTrace Logo

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

NCT03467178 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2021-09-05

No results posted yet for this study

Summary

Multicenter Phase II study on Decitabine-Carboplatin combination in platinum resistant ovarian cancer patients.

Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances occur, intolerable toxicities occur, or the patient withdraws consent.

Conditions

  • Recurrent, Platinum-resistant Ovarian Cancer

Interventions

DRUG

Decitabine

Nucleic Acid Synthesis Inhibitor

DRUG

Carboplatin

Chemotherapy medication

DRUG

Pegylated Liposomal Doxorubicin

Chemotherapy medication

DRUG

Gemcitabine

Chemotherapy medication

DRUG

Paclitaxel

Chemotherapy medication

Sponsors & Collaborators

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Principal Investigators

  • Domenica Lorusso, MD · National Cancer Institute (NCI)

  • Domenica Lorusso, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-30
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03467178 on ClinicalTrials.gov